RxDoctor Payments Data

Jessica Al Khalidi, NP

Family · San Antonio, TXNPI 1760143275

Payments from drug & device makers

$6,247in general payments, 2019–2025

Across 286 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$926
  • Takeda Pharmaceuticals U.S.A., Inc.$530
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$463
  • Ardelyx, Inc.$325
  • Sanofi$324
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$6,10198%
  • Education$1462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,247 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$85,841
Medicare patients
225
Services billed
3,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide83$60,924
XifaxanRifaximin15$50,587
TrulancePlecanatide30$23,527
Omeprazole245$5,182
ClenpiqSod Picosulf/Mag Ox/Citric Ac21$3,457
Dexlansoprazole DrDexlansoprazole14$3,089
Famotidine138$2,847
Pantoprazole Sodium167$2,426
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C16$2,192
Ursodiol15$2,138
Lubiprostone12$1,915
Esomeprazole Magnesium17$1,614
Ondansetron OdtOndansetron45$1,078
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl53$859
Dicyclomine Hcl74$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$463$76,30661 claims
AbbVieLinzess$926$60,92483 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →